HEALTH
### NHS Scotland’s Weight Loss Jab Programme Sees Scant Uptake Three Years Post-Approval
**Edinburgh, Scotland** – Fewer than 800 individuals in Scotland have received the new generation of weight-loss medication jabs on the NHS, despite the treatments being approved for use three years ago. This revelation comes from a BBC News investigation, raising questions about the rollout and accessibility of these potentially transformative drugs across the nation.
The figures underscore a significant disparity between the clinical approval of these medications and their actual availability to patients struggling with obesity. Approved for NHS use in 2021, these treatments, including drugs like Semaglutide (known commercially as Wegovy) and Liraglutide (Saxenda), are part of a class of medications called GLP-1 receptor agonists. They work by mimicking a natural hormone that helps regulate appetite and blood sugar levels, leading to significant weight reduction for eligible individuals.
Eligibility for these treatments on the NHS is typically stringent, reserved for individuals with a high Body Mass Index (BMI) and often co-morbidities such as type 2 diabetes or heart disease, who have not achieved significant weight loss through other interventions. These drugs represent a considerable medical advancement, offering a new tool in the ongoing battle against obesity, a condition that places immense strain on public health resources.
Several factors could contribute to the notably low uptake. Potential reasons include global supply chain issues impacting the availability of the drugs, the significant cost implications for health boards, and the need for robust clinical pathways and specialist support for prescribing and monitoring patients. Furthermore, there may be a lack of widespread awareness or clear, consistent guidelines for primary care practitioners across all NHS Scotland regions.
Obesity remains a major public health challenge across Scotland, with a substantial proportion of the adult population classified as overweight or obese. While lifestyle interventions involving diet and exercise are foundational, pharmacological treatments offer an additional, evidence-based option for those for whom traditional methods alone are insufficient.
The slow deployment of these approved medications suggests potential bottlenecks in the system designed to integrate new treatments. As demand for effective obesity management solutions continues to grow, pressure is likely to mount on health authorities to accelerate the rollout and ensure that eligible patients across Scotland can access these clinically approved and potentially life-changing therapies.
